ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient outcomes"

  • Abstract Number: 2359 • 2018 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients

    Isabela Bertoglio1, Glaucia Abrahão1, Eloisa Bonfa2 and Michelle Lopes3, 1Rheumatology, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Now-a-days there is a growing trend of switching to a more patient-centered healthcare system, with a widespread use of patient-reported outcomes (PROs). However, most…
  • Abstract Number: 2360 • 2018 ACR/ARHP Annual Meeting

    Perceptions of Patients with Rheumatoid Arthritis about Self-Assessment of Disease Activity after Watching an Educational Video: Qualitative Pilot Results from the Auto-DAS in Middle Eastern Arab Countries Study

    Nelly Ziade1, Sahar Saad2, Manal al Mashaleh3, Lina el Kibbi4, Bassel el Zorkany5, Humeira Badsha6, Ghita Harifi6, Amani Daher7, Nelly Salloum8, Basel Masri9 and Thurayya Arayssi10, 1Rheumatology, Saint-Joseph University, Beirut, Lebanon, 2Rheumatology, King Hamad University Hospital, Bahrain, Bahrain, 3Rheumatology, King Hussein Medical Center, Royal Medical Services, Amman, Jordan, 4Rheumatology, Specialized Medical Center, Riyadh, Saudi Arabia, 5Rheumatology, Cairo University, Cairo, Egypt, 6Dr. Humeira Badsha Medical Center, Dubai, United Arab Emirates, 7Medicine, Saint-Joseph University, Beirut, Lebanon, 8Registered Nurse, Beirut, Lebanon, 9Rheumatology, Jordan Hospital, Amman, Jordan, 10Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar

    Background/Purpose: Empowering RA patients through education is linked to improved adherence, treatment decisions and speeding up the assessment process during consultation. The purpose of the…
  • Abstract Number: 2369 • 2018 ACR/ARHP Annual Meeting

    Patients Preference Goes to MTX Autoinjectors over Prefilled Syringes: Results from a Phase III Trial

    Alain Saraux1, Christophe Hudry2, Elena Zinovieva3, Agnès Courbeyrette4 and Hélène Herman-Demars3, 1Rheumatology, CHU Brest, Brest, France, 2AP-HP Hôpital Cochin, Paris, France, 3Medical Department Nordic Pharma, Paris, France, 4Medical Departement, Nordic Pharma, Paris, France

    Background/Purpose: The offer of injectable MTX worldwide expanded during past few years with different types of enhanced devices such as prefilled syringes and autoinjector pens.…
  • Abstract Number: 2470 • 2018 ACR/ARHP Annual Meeting

    The Impact of Frailty on Changes in Physical Function Among Adults with Rheumatoid Arthritis

    James Andrews1, Laura Trupin2, Catherine Hough1, Edward H. Yelin3 and Patricia Katz2, 1Medicine, University of Washington, Seattle, WA, 2University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Frailty is a state of excess vulnerability to stressors and is associated with increased risk of poor health outcomes including physical disability. Frailty and…
  • Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting

    Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study

    Anthony Turkiewicz1, Amanda M. Gellett2, Lisa Kerr2, Julie Birt2 and Jordi Gratacos3, 1Rheumatology Associates, Birmingham, AL, 2Eli Lilly and Company, Indianapolis, IN, 3Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain

    Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
  • Abstract Number: 326 • 2018 ACR/ARHP Annual Meeting

    Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures

    Malka Forman1, Cianna Leatherwood2, Chang Xu1, Eunji Ko1, Bing Lu3, Maura D. Iversen4, Daniel Solomon2 and Sonali Desai2, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Changing clinical practice patterns and incorporation patient-reported outcome measures (PROMs) for disease activity assessment into routine workflow is challenging. We sought to integrate a…
  • Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting

    Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Alexis Ogdie1, Mei Liu2, Meghan Glynn2, Kelechi Emeanuru2, Leslie R Harrold3, Sven Richter4, Benoit Guerette4 and Philip J. Mease5, 1University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Celgene Corporation, Summit, NJ, 5Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
  • Abstract Number: 408 • 2018 ACR/ARHP Annual Meeting

    State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief

    Emma Lape1, Faith Selzer1,2, Jamie E. Collins3,4, Elena Losina1,4 and Jeffrey N. Katz1,4, 1Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, 3Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 4Harvard Medical School, Boston, MA

    Background/Purpose: Pain catastrophizing and widespread pain (WP) —constructs reflecting cognitive processes during the pain experience—predict disability, pain chronicity/severity, and lower quality of life in a…
  • Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting

    Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials

    Liana Fraenkel1, W. Benjamin Nowell2, Carole Wiedmeyer2, Zhenglin Wei3, Kaleb Michaud4, Tuhina Neogi5, Christine Ramsey1 and David Broniatowski3, 1Yale University School of Medicine, New Haven, CT, 2Global Healthy Living Foundation, Upper Nyack, NY, 3George Washington University, Washington, DC, 4Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting

    Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients

    Jens Gert Kuipers1, Michael Koller2, Ulrich Rueffer3, Florian Zeman2, Karolina Mueller4 and Joachim Weis5, 1Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, 2Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3German Fatigue Society, Cologne, Germany, 4Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 5University Clinic Centre Freiburg, Freiburg, Germany

    Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
  • Abstract Number: 1263 • 2017 ACR/ARHP Annual Meeting

    Relevance and Utility of Patient Reported Outcomes Measurement Information System (PROMIS®) Instruments in SLE: A Qualitative Study

    Shanthini Kasturi1, Madeline Epsten2, Adena Batterman3, Roberta Horton3, Juliette Kleinman3, Jillian Rose3, Jackie Szymonifka2, Laura Robbins4 and Lisa A. Mandl1, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Social Work Programs, Hospital for Special Surgery, New York, NY, 4Education & Academic Affairs, Hospital for Special Surgery, New York, NY

    Background/Purpose: The measurement of patient reported outcomes is a priority for patient-centered high value care. This is particularly true in chronic systemic diseases such as…
  • Abstract Number: 1306 • 2017 ACR/ARHP Annual Meeting

    Predictors of Contraceptive Use Among Reproductive-Age Women with Rheumatic Diseases

    Mehret Birru Talabi1 and Sonya Borrero2, 1Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Contraception helps reproductive-age women with rheumatic diseases to avoid or plan pregnancies so that disease quiescence on safe medications may first be achieved. However,…
  • Abstract Number: 1351 • 2017 ACR/ARHP Annual Meeting

    Minimal Clinically Important Improvement (MCII) of RAPID3 (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3), an INDEX of ONLY Patient Self-Report Scores in Rheumatoid Arthritis (RA): Similar  Performance to DAS28 and CDAI

    Michael Ward1, Isabel Castrejón2, Martin J. Bergman3, Lori C. Guthrie4, Maria I. Alba4 and Theodore Pincus2, 1NIH/NIAMS, Bethesda, MD, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Drexel University College of Medicine, philadelphia, PA, 4NIAMS/NIH, Bethesda, MD

    Background/Purpose: No single “gold standard” measure is available to assess patients with rheumatoid arthritis (RA) in clinical trials and routine care, as in hypertension, diabetes,…
  • Abstract Number: 1804 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes and Damage Predict Mortality in Lupus

    Desiree R Azizoddin1, Meenakshi Jolly2, Patricia P. Katz3 and Edward H. Yelin4, 1Department of Psychology, Loma Linda University, Loma Linda, CA, 2Rush, Chicago, IL, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Physician-assessed disease activity and damage predict mortality in systemic lupus erythematosus (SLE). Patient-reported outcomes (PROs) are known predictors of mortality in other chronic diseases,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology